Enfortumab vedotin for Metastatic Castration-resistant Prostate Cancer

Phase-Based Progress Estimates
Metastatic Castration-resistant Prostate CancerEnfortumab vedotin - Drug
What conditions do you have?

Study Summary

This trial is testing a new cancer drug, enfortumab, alone and in combination with other cancer drugs. The trial will start with testing enfortumab by itself (monotherapy), and additional groups (cohorts) may be added later as new drug combinations are found.

Eligible Conditions
  • Metastatic Castration-resistant Prostate Cancer

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 12 months

12 months
Proportion subjects achieving one of the following: Objective response by RECIST1.1, Confirmed conversion of circulating tumor cell count (CTC) to <5/7.5 mL blood, PSA decline ≥ 50% (PCWG3), or Stable disease ≥ 6 months per PCWG3 mod.RECIST 1.1

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

1 Treatment Group

Treatment: all patients
1 of 1

Experimental Treatment

34 Total Participants · 1 Treatment Group

Primary Treatment: Enfortumab vedotin · No Placebo Group · Phase 2

Treatment: all patients
Experimental Group · 1 Intervention: Enfortumab vedotin · Intervention Types: Drug
First Studied
Drug Approval Stage
How many patients have taken this drug
Enfortumab vedotin
FDA approved

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 12 months

Who is running the clinical trial?

Astellas Pharma IncIndustry Sponsor
679 Previous Clinical Trials
213,283 Total Patients Enrolled
University of UtahLead Sponsor
1,003 Previous Clinical Trials
1,785,120 Total Patients Enrolled
2 Trials studying Metastatic Castration-resistant Prostate Cancer
69 Patients Enrolled for Metastatic Castration-resistant Prostate Cancer
Umang Swami, MDPrincipal InvestigatorHuntsman Cancer Institute
1 Previous Clinical Trials
33 Total Patients Enrolled
1 Trials studying Metastatic Castration-resistant Prostate Cancer
33 Patients Enrolled for Metastatic Castration-resistant Prostate Cancer

Eligibility Criteria

Age 18+ · Male Participants · 10 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you: